



PRESS RELEASE

Efor Expands U.S. CQV Capabilities Through the Addition of Gills Process Control

Lyon, France – July 1, 2026 – Efor, a global leader in quality and compliance services for the life sciences industry, today announced the addition of Gills Process Control (GPCi), a North Carolina-based specialist in Commissioning, Qualification and Validation (CQV).

The move marks another milestone in Efor's U.S. growth strategy, as the company continues to strengthen its presence in the world's largest life sciences market. Efor plans to generate €70 million in U.S. revenue in 2026 and has set a target of exceeding €400 million by 2030.

The United States at the Center of Efor's Growth Strategy

Since establishing its presence in Boston in 2023, Efor has made the United States a strategic priority and a major driver of its global growth strategy. Today, the U.S. market represents one of the company's most significant growth opportunities, with Efor supporting leading pharmaceutical and biotechnology companies on some of their most critical manufacturing and operational initiatives.

The addition of Gills Process Control represents another important step in executing that strategy. Founded in 1995, GPCi has built a strong reputation for delivering high-quality CQV services to pharmaceutical and biotechnology manufacturers and further strengthens Efor's footprint in North Carolina, one of the most dynamic life sciences hubs in the United States.

Strengthening Expertise to Support Complex Industrial Projects



Gills Process Control brings deep technical expertise and a strong operational alignment with Efor's core service offerings. The company has established itself as a trusted partner for life sciences manufacturers seeking support in commissioning, qualification, validation and regulatory compliance activities.

By combining the agility and local market knowledge of GPCi with Efor's international scale and technical resources, the group further enhances its ability to support increasingly complex projects across pharmaceutical, biotechnology and medical device industries.

*From left to right : Patrick O. Hayes, Joey Paris, Mickael Pretot, John Gills and Ludo Frequelin
Copyright Efor*

As a partner to the world's 20 largest pharmaceutical companies, Efor intends to continue its growth trajectory, helping them address growing challenges related to quality assurance, regulatory compliance and manufacturing excellence.

"We are delighted to welcome the Gill's Process Control team to Efor Group. Throughout our discussions, we met passionate professionals who share our commitment to technical excellence, our quality-driven culture, and our dedication to supporting the Life Sciences industry. Their expertise, deep understanding of the U.S. market, and unwavering commitment to their clients will be invaluable assets as we continue to deliver major projects for our clients across the United States."


"This acquisition is fully aligned with our strategy to consolidate a highly fragmented market. We are committed to bringing together the industry's leading specialists around a shared vision and building a leading Life Sciences consulting group in the United States and beyond." said Mathieu Roger, Founder and CEO of Efor.



"Joining Efor creates exciting opportunities for both our employees and our clients. We share the same commitment to quality, operational excellence and customer success. Together, we will be able to accelerate our growth, expand our capabilities and deliver even greater value to the life sciences organizations we serve." said John Gill, President of Gills Process Control.

With this new milestone, Efor continues to execute a strategy that combines sustained organic growth with targeted acquisitions, strengthening its expertise wherever its clients are investing.

This trajectory reflects a clear ambition: to build the global leader in quality and compliance for the Life Sciences industry and surpass €1 billion in revenue by 2030.



About Efor Group

Founded in 2013, Efor Group is now a leading international player specializing in quality and regulatory compliance for the healthcare industries. With more than 3,000 employees across 19 countries, the Group supports global leaders in the pharmaceutical, biotechnology, and medical device sectors in ensuring the compliance of their manufacturing sites and accelerating the delivery of innovative therapeutic solutions to patients.

Its mission is to remove technical and regulatory barriers so that innovation can reach patients faster, under the highest standards of safety and reliability.

Committed to becoming a global leader while remaining true to its founding values, Efor Group fully integrates social and environmental priorities into its operations. Through concrete initiatives that support society, sustainability, and innovation, the Group pursues a long-term growth vision guided by excellence, commitment, and collaboration.



efor.com



About Gill Process Controls

Founded in 1995 in Rocky Mount, North Carolina, Gills Process Control (GPCi) specializes in Commissioning, Qualification and Validation (CQV) services for the pharmaceutical and biotechnology industries. With nearly three decades of experience, the company supports manufacturers in the qualification of equipment, systems and facilities, as well as ensuring compliance across regulated production environments.

Recognized for its technical expertise, deep understanding of regulatory requirements and close partnerships with industry stakeholders, Gills Process Control supports clients throughout the entire lifecycle of industrial projects, helping ensure quality, compliance and operational reliability.



gillsprocess.com



Press Contact

Floriane CARRET



+33 6 89 42 79 02



floriane.carret@efor-group.com



Committed to Excellence